申请人:GLAXOSMITHKLINE LLC
公开号:WO2013096153A1
公开(公告)日:2013-06-27
The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
本发明涉及取代喹啉衍生物。具体而言,本发明涉及根据公式I的化合物:其中R,R1,R2,R3和R4按如下定义。本发明的化合物是乳酸脱氢酶A的抑制剂,可用于治疗癌症和与肿瘤细胞代谢有关的疾病,例如癌症,更具体地说是乳腺癌、结肠癌、前列腺癌和肺癌。因此,本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗与之相关的疾病的方法。